NLGN3: A Potential Drug Target and Biomarker (G54413)

Target Name: NLGN3

NCBI ID: G54413

NLGN3

NLGN3: A Potential Drug Target and Biomarker

Non-coding RNA (ncRNA) molecules have been identified as key regulators in various biological processes. One such molecule is NLGN3, which is a non-coding RNA gene that has been identified to play a critical role in various cellular processes. NLGN3 is a potential drug target and biomarker that can be targeted to treat various diseases, including cancer, neurodegenerative diseases, and respiratory disorders.

NLGN3 is a member of the NLGN family, which includes several similar non-coding RNAs that are involved in the regulation of gene expression. The NLGN family is characterized by the presence of a specific domain, known as the NLGN3-specific domain, which is responsible for NLGN3's unique functions. The NLGN3-specific domain is a transmembrane protein that contains several conserved protein-coding sequences and is involved in the formation of a complex with other non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs).

The functions of NLGN3 and its associated domains have been extensively studied in various organisms, including humans. Several studies have demonstrated that NLGN3 is involved in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. NLGN3 has also been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and respiratory disorders.

As a potential drug target, NLGN3 is an attractive target for drug developers because of its unique functions and the potential impact it can have on human health. One of the main advantages of NLGN3 as a drug target is its high stability, which allows for the production of recombinant proteins that can be used in drug studies. Additionally, NLGN3 is a protein that is expressed in various tissues and cells, which makes it an attractive target for drug development because it can be easily administered to humans.

In addition to its potential as a drug target, NLGN3 has also been identified as a potential biomarker for various diseases. The expression of NLGN3 has been shown to be affected by various diseases, including cancer, neurodegenerative diseases, and respiratory disorders. For example, studies have shown that the expression of NLGN3 is downregulated in various cancer tissues, and that increasing the expression of NLGN3 can inhibit the growth of cancer cells. Additionally, studies have shown that the expression of NLGN3 is affected by neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and that increasing the expression of NLGN3 can exacerbate the symptoms of these diseases.

Furthermore, some studies have also shown that the expression of NLGN3 is affected by respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and asthma. Studies have shown that the expression of NLGN3 is downregulated in various respiratory disorders tissues and that increasing the expression of NLGN3 can improve the symptoms of these disorders.

In conclusion, NLGN3 is a potential drug target and biomarker that can be used to treat various diseases. Its unique functions and high stability make it an attractive target for drug development, while its potential as a biomarker makes it an attractive target for diagnostic studies. Further research is needed to fully understand the functions of NLGN3 and its potential as a drug and biomarker.

Protein Name: Neuroligin 3

Functions: Cell surface protein involved in cell-cell-interactions via its interactions with neurexin family members. Plays a role in synapse function and synaptic signal transmission, and may mediate its effects by clustering other synaptic proteins. May promote the initial formation of synapses, but is not essential for this. May also play a role in glia-glia or glia-neuron interactions in the developing peripheral nervous system (By similarity)

The "NLGN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NLGN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets